Torrid (CURV) Q4 2025 Earnings Call Transcript

Torrid reported FY2025 net sales of $1.0B and adjusted EBITDA of $63.6M (beat guidance), while Q4 sales fell to $236.2M from $275.6M and comparable sales declined 10% (460bps Q4 impact from paused footwear). Q4 gross margin compressed to 30% (down ~360bps YoY), net loss widened to $8.1M, but SG&A fell $11.4M and store optimization delivered ~$18.5M in 2025 with a targeted incremental $40M savings in 2026. Balance sheet and operating metrics: $200M cash, $84.9M total liquidity, inventory $136.5M (-8%), 151 stores closed in 2025 with up to 30 more planned; 2026 guidance calls for $940–960M sales, $65–75M adjusted EBITDA, and $8–10M CapEx, while sub-brands are expected to grow ~60% to ~$110M and footwear reintroduction should improve comps in H2 2026.

Analysis

The company has transitioned from a defensive restructure to an execution-dependent growth phase; upside now hinges less on cost cuts and more on marketing ROAS, product cadence, and the timing of category restarts. Because operating leverage is baked into the new cost base, incremental top-line recovery will flow disproportionately to EBITDA — but only if reactivation and new-customer economics meet conservative unit-economics thresholds.

Second-order winners include footwear and limited-run suppliers that can scale quickly with lower working-capital swings, and trade partners that offer tariff-mitigation (nearshoring, bonded-warehouse models). Mall-heavy competitors lacking a disciplined omnichannel migration are the natural losers: this company’s tighter store fleet plus digital-first retention creates a two-way margin squeeze on peers that must subsidize lower-productivity locations.

Key risks are execution-related and time-phased: a sustained front-half sales drag (from category timing or macro softness) could consume the realized benefit of structural cost saves; conversely, a clean mid-year product cadence and stronger-than-modeled reactivation would be a convex catalyst. Watch quarterly ROAS, loyalty frequency delta, and gross-margin per unit rather than headline EBITDA alone — those metrics will signal whether guidance is durable or optimistic.

Key Decisions for Investors

• Long CURV via a limited-risk call spread aimed at H2 2026 product/campaign catalysts: buy a 6–12 month call spread (e.g., Jul–Jan strikes) to capture a potential re-acceleration when footwear and new intimate assortments scale. Rationale: asymmetric upside if reactivation converts; defined premium loss if front-half headwinds persist. Size small (1–2% net exposure) and roll on confirmed improvement in ROAS and gross-margin/unit.
• On any >15% post-earnings pullback, initiate a partial-covered position: buy CURV stock and simultaneously purchase a 6–9 month out-of-the-money protective put (collar-lite). Rationale: protects downside from consumer shock while leaving meaningful upside to H2 delivery; target reward-to-risk ~2:1 if reactivation metrics normalize within 6–9 months.
• Relative-value pair: go long CURV / short XRT (retail ETF) or a mall-centric specialty operator for 6–12 months to isolate company-specific execution. Rationale: isolates omnichannel and product-driven outperformance versus macro retail cyclicality; hedge macro-driven downside. Trim if overall retail sentiment deteriorates sharply.
• Volatility play around Q1 print: if IV spikes into the release, sell a put spread (defined risk) and use proceeds to buy a single-call vertical further out to monetize IV and maintain upside optionality. Rationale: captures premium-rich environment while preserving directional upside if management proves reactivation acceleration.